IQVIA Announces Upsizing of its Allocation of New Term B Loans
ncarol.com/10242793

INNOVATION PARK, N.C. ~ IQVIA Holdings Inc. (NYSE:IQV) announced today that its wholly-owned subsidiary, IQVIA Inc., has allocated a new term B loan due 2031 of approximately $1,500 million. This loan was upsized due to lender demand.

The proceeds from the new term loan B and the offering of $1,250 million in aggregate principal amount of senior secured notes due 2029 will be used to repay outstanding Euro-denominated and U.S.-denominated term B loans under the Borrower's senior secured credit facilities, as well as to pay fees and expenses related to the Borrower's Notes offering and the Borrower's credit agreement amendment in respect of the New Term Loan B.

In connection with the allocation of the New Term Loan B, IQVIA entered into a cross-currency swap agreement which will effectively convert the New Term Loan B into a euro-denominated borrowing at prevailing euro interest rates to hedge exposure to USD-denominated indebtedness created by the New Term Loan B. The effective net borrowing rate to IQVIA will be 4.9015%, inclusive of the yield on the New Term Loan B and the beneficial impact of the cross-currency swap.

More on ncarol.com

• Mother Launches National Movement After College Athlete Hospitalized During Punishment Workout
• From Cheer to Courtroom: The Hidden Legal Risks in Your Holiday Eggnog
• Controversial Vegan Turns Rapper Launches First Song, "Psychopathic Tendencies."
• Inside the Fight for Affordable Housing: Avery Headley Joins Terran Lamp for a Candid Bronx Leadership Conversation
• Canterbury Hotel Group Announces the Opening of the TownePlace Suites by Marriott Portland Airport

IQVIA is a leading global provider of advanced analytics, technology solutions, and clinical research services to life sciences industry. It creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 87,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is also a global leader in protecting individual patient privacy by using a wide variety of privacy-enhancing technologies and safeguards while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with precise treatment paths for better outcomes.

The company's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances in an effort to advance their path toward cures.

---

Show All News | Report Violation